Disclosure: This article may contain affiliate links. If you click and make a purchase, we may earn a commission at no extra cost to you. We only recommend platforms we believe provide genuine value. See our full disclosure.
The conversation about testosterone therapy gets more nuanced with age. For younger men with clear-cut hypogonadism, the risk-benefit calculus is usually straightforward. For men over 60, the evidence is more layered — but increasingly encouraging. Here's what the major clinical trials actually show.
The T-Trials: What We Learned
The Testosterone Trials enrolled 790 men aged 65+ with confirmed low testosterone and symptoms. After one year of testosterone gel, participants showed meaningful improvements in sexual function (the most consistent benefit), walking distance and physical performance, mood and depressive symptoms, and bone mineral density (particularly in the spine).
These weren't dramatic transformations, but they were consistent, clinically meaningful improvements across multiple domains of health that matter deeply to quality of life after 60.
Key finding: The T-Trials showed that testosterone therapy in men 65+ improved sexual function, physical performance, mood, and bone density — with the strongest effects on sexual function.
Cardiovascular Safety: The TRAVERSE Trial
The biggest concern for older men has always been cardiovascular risk. The TRAVERSE trial — a landmark 5,000+ patient safety study — provided reassuring results: TRT did not significantly increase the risk of major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in men aged 45–80 with cardiovascular disease or high risk. The 2025 FDA labeling update removed prior cardiovascular warning language based on this data.
However, TRAVERSE did show numerical increases in atrial fibrillation, acute kidney injury, and pulmonary embolism. These weren't statistically significant primary outcomes, but they underscore the importance of careful monitoring — especially in men with pre-existing heart conditions.
Special Considerations After 60
Older men on TRT need more vigilant monitoring. Erythrocytosis (elevated red blood cell count) is more common with age and can increase clot risk. PSA should be tracked regularly for prostate health. Blood pressure monitoring matters, given the 2025 FDA blood pressure warning. Drug interactions are more likely with polypharmacy. And the distinction between normal aging and pathological hypogonadism becomes more important — not every 65-year-old with testosterone of 350 ng/dL needs treatment.
When TRT Makes Sense After 60
The best candidates are men with confirmed low testosterone (two morning levels below 300 ng/dL), clear symptoms that impair quality of life, no untreated prostate cancer or severe heart failure, willingness to commit to regular monitoring, and realistic expectations (improvement, not transformation).
Telehealth for Ongoing Management
For men over 60, the monitoring component of TRT is arguably more important than initiation. Regular lab work, symptom check-ins, and dose adjustments are essential. Telehealth makes this ongoing management dramatically more accessible — no driving to clinics for 15-minute follow-ups. Platforms can coordinate lab work at local facilities and review results by video. For men with mobility limitations, this can be the difference between proper monitoring and none at all.
If you're dealing with ED after 50, some of it may be testosterone-related — but it's important to evaluate both independently.
Compare telehealth providers for testosterone treatment — with licensed physicians and home delivery.
Compare Providers →TRT after 60 isn't for everyone, but for the right patient with the right monitoring, it can meaningfully improve sexual function, energy, mood, and bone health during a period of life when these things matter enormously.